Corcept Therapeutics is trading at $111.55 (20% up) in after-hours trading after reporting second quarter 2026 results that significantly beat Wall Street estimates.
- The company's performance was driven by a strong launch of the oncology drug Lifyorli and solid growth in its Cushing’s syndrome segment.
- Corcept raised its full-year 2026 revenue guidance to $1.1–$1.2 billion, signaling stronger-than-expected growth momentum.
- The earnings beat and optimistic outlook have driven significant bullish demand for the stock following the report.